Abiopharma

Labeling changes approved for HIKMA. Active ingredient: OXYCODONE HYDROCHLORIDE. Decision date: 01/06/2026

Labeling changes approved for VISTAPHARM LLC. Active ingredient: OXYCODONE HYDROCHLORIDE. Decision date: 01/06/2026

Final approval of ANDA #ANDA #212141 for SUCRALFATE. Decision date: 01/05/2026

NASDAQ symbol attribute type Security_Name was changed. Previous value: Mind Medicine (MindMed) Inc. - Common Shares. New value: Denium Therapeutics, Inc - Common Shares.

NASDAQ symbol attribute type Security_Name was changed. Previous value: iRhythm Technologies, Inc. - Common Stock. New value: iRhythm Holdings, Inc. - Common Stock.

Notification regarding unquoted securities - MSB

Application for quotation of securities - MSB

Appendix 3Y for Eric Rose

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

Final approval of ANDA #ANDA #218188 for FUROSEMIDE. Decision date: 01/08/2026

Final approval of ANDA #ANDA #219511 for SAPROPTERIN DIHYDROCHLORIDE. Decision date: 01/08/2026

Final approval of ANDA #ANDA #217216 for EVEROLIMUS. Decision date: 01/09/2026

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

Heery Christopher 🟡 adjusted position in 6.9K shares of Arcellx, Inc. (ACLX) at $64.15 Transaction Date: Jan 12, 2026 | Filing ID: 010889

📋 Panacea Innovation Ltd (10% Stockholder) plans to sell 40K shares of Atara Biotherapeutics, Inc. (at $5.88 each, total $235K) Filed: Jan 12, 2026 | ID: 010883